OncoMatch/Clinical Trials/NCT06952478
A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Is NCT06952478 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including CT-P44(Daratumumab) and Darzalex Faspro(Daratumumab) for refractory or relapsed multiple myeloma.
Treatment: CT-P44(Daratumumab) · Darzalex Faspro(Daratumumab) — This study is a phase 1/3 study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Multiple Myeloma
Prior therapy
Must have received:
Patient must have achieved a response (PR or better based on investigator's determination of response by the IMWG criteria) to at least one prior regimen. Patient must have a PD as defined by the IMWG criteria on or after their last line of therapy.
Cannot have received: CD38-targeted therapy (daratumumab)
Patient has received daratumumab or any other drug specifically targeting CD38 previously.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06952478 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CD38-targeted therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages